In last trading session, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) saw 1.53 million shares changing hands with its beta currently measuring 0.49. Company’s recent per share price level of $5.00 trading at $0.21 or 4.38% at ring of the bell on the day assigns it a market valuation of $348.18M. That closing price of PHAT’s stock is at a discount of -294.2% from its 52-week high price of $19.71 and is indicating a premium of 13.6% from its 52-week low price of $4.32. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.37 million shares which gives us an average trading volume of 1.07 million if we extend that period to 3-months.

For Phathom Pharmaceuticals Inc (PHAT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 10 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.06 in the current quarter.

Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information

Upright in the green during last session for gaining 4.38%, in the last five days PHAT remained trading in the red while hitting it’s week-highest on Thursday, 03/06/25 when the stock touched $5.00 price level, adding 28.37% to its value on the day. Phathom Pharmaceuticals Inc’s shares saw a change of -38.42% in year-to-date performance and have moved -17.76% in past 5-day. Phathom Pharmaceuticals Inc (NASDAQ:PHAT) showed a performance of -7.58% in past 30-days. Number of shares sold short was 13.92 million shares which calculate 13.68 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 18 to the stock, which implies a rise of 72.22% to its current value. Analysts have been projecting 18 as a low price target for the stock while placing it at a high target of 18. It follows that stock’s current price would drop -260.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -260.0% for stock’s current value.

Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts

This year revenue growth is estimated to rise 195.33% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 27.75M for the same. And 7 analysts are in estimates of company making revenue of 36.86M in the next quarter. Company posted 1.91M and 7.32M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 12.50% during past 5 years.

Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s Major holders

Insiders are in possession of 3.77% of company’s total shares while institution are holding 97.55 percent of that, with stock having share float percentage of 101.37%. Investors also watch the number of corporate investors in a company very closely, which is 97.55% institutions for Phathom Pharmaceuticals Inc that are currently holding shares of the company. FRAZIER LIFE SCIENCES MANAGEMENT, L.P. is the top institutional holder at PHAT for having 10.11 million shares of worth $104.13 million. And as of 2024-06-30, it was holding 17.2637 of the company’s outstanding shares.

The second largest institutional holder is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD, which was holding about 7.46 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.7473 of outstanding shares, having a total worth of $76.89 million.

On the other hand, Invesco Global Fund and PGIM Jennison Health Sciences Fd are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 1.98 shares of worth $9.88 million or 2.84% of the total outstanding shares. The later fund manager was in possession of 1.78 shares on Dec 31, 2024 , making its stake of worth around $8.91 million in the company or a holder of 2.56% of company’s stock.